title: U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
abstract: The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and consultation with national experts who met in Atlanta, Georgia, during August 26-28, 2015. The information in this report updates the 2010 U.S. MEC (CDC. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR 2010:59 [No. RR-4]). Notable updates include the addition of recommendations for women with cystic fibrosis, women with multiple sclerosis, and women receiving certain psychotropic drugs or St. John's wort; revisions to the recommendations for emergency contraception, including the addition of ulipristal acetate; and revisions to the recommendations for postpartum women; women who are breastfeeding; women with known dyslipidemias, migraine headaches, superficial venous disease, gestational trophoblastic disease, sexually transmitted diseases, and human immunodeficiency virus; and women who are receiving antiretroviral therapy. The recommendations in this report are intended to assist health care providers when they counsel women, men, and couples about contraceptive method choice. Although these recommendations are meant to serve as a source of clinical guidance, health care providers should always consider the individual clinical circumstances of each person seeking family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. Persons should seek advice from their health care providers when considering family planning options.
authors.affiliation: Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, Georgia.
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Curtis
authors.forename: Naomi K
authors.initials: NK
authors.lastname: Tepper
authors.forename: Tara C
authors.initials: TC
authors.lastname: Jatlaoui
authors.forename: Erin
authors.initials: E
authors.lastname: Berry-Bibee
authors.forename: Leah G
authors.initials: LG
authors.lastname: Horton
authors.forename: Lauren B
authors.initials: LB
authors.lastname: Zapata
authors.forename: Katharine B
authors.initials: KB
authors.lastname: Simmons
authors.forename: H Pamela
authors.initials: HP
authors.lastname: Pagano
authors.forename: Denise J
authors.initials: DJ
authors.lastname: Jamieson
authors.forename: Maura K
authors.initials: MK
authors.lastname: Whiteman
mesh_terms: D003267:Contraception / Q000379:methods; D003270:Contraceptive Agents / Q000627:therapeutic use*; D000075202:Contraindications; D004608:Eligibility Determination; D005193:Family Planning Services; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D049168:Pregnancy, Unplanned; D018570:Risk Assessment; D014481:United States
chemical_list: D003270:Contraceptive Agents